Background Data on prevalence and incidence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection in Rwanda are scarce. Methods HBV status was assessed at baseline and Month 12, and anti-HCV antibodies at baseline, in a prospective cohort study of HIV-infected patients in Kigali, Rwanda: 104 men and 114 women initiating antiretroviral therapy (ART) at baseline, and 200 women not yet eligible for ART. Results Baseline prevalence of active HBV infection (HBsAg positive), past or occult HBV infection (anti-HBc positive and HBsAg negative) and anti-HCV was 5.2%, 42.9%, and 5.7%, respectively. The active HBV incidence rate was 4.2/1,000 person years (PY). In a multivariable logistic regression model using baseline data, participants with WHO stage 3 or 4 HIV disease were 4.19 times (95% CI 1.21–14.47) more likely to have active HBV infection, and older patients were more likely to have evidence of past exposure to HBV (aRR 1.03 per year; 95%CI 1.01–1.06). Older age was also positively associated with having anti-HCV antibodies (aOR 1.09; 95%CI 1.04–1.14) while having a higher baseline HIV viral load was negatively associated with HCV (aOR 0.60; 95% CI 0.40–0.98). The median CD4 increase during the first 12 months of ART was lower for those with active HBV infection or anti-HCV at baseline. Almost all participants (88%) with active HBV infection who were on ART were receiving lamivudine monotherapy for HBV. Conclusion HBV and HCV are common in HIV-infected patients in Rwanda. Regular HBsAg screening is needed to ensure that HIV-HBV co-infected patients receive an HBV-active ART regimen, and the prevalence of occult HBV infection should be determined. Improved access to HBV vaccination is recommended. Active HCV prevalence and incidence should be investigated further to determine whether HCV RNA PCR testing should be introduced in Rwanda.
References
[1]
Alter MJ (2003) Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 39 (Suppl 1)S64–69.
[2]
Edmunds WJ, Medley GF, Nokes DJ, O’Callaghan CJ, Whittle HC, et al. (1996) Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 117: 313–325.
[3]
Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, et al. (1999) Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol 58: 111–115.
[4]
Lavanchy D (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97–107.
[5]
Shepard CW, Finelli L, Alter MJ (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558–567.
[6]
Arshad M, El-Kamary SS, Jhaveri R (2011) Hepatitis C virus infection during pregnancy and the newborn period – are they opportunities for treatment? J Viral Hepat 18: 229–236.
[7]
Burnett RJ, Fran？ois G, Kew MC (2005) Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int 25: 201–213.
[8]
Barth RE, Huijgen Q, Taljaard J, Hoepelman AI (2010) Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 14: e1024–e1031.
[9]
Hoffmann CJ, Thio CL (2007) Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7: 402–409.
[10]
Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, et al. (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921–1926.
[11]
Nunez M, Ramos B, Diaz-Pollan B, Camino N, Martín-Carbonero L, et al. (2006) Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Human Retroviruses 22: 842–848.
[12]
Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, et al. (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterol. 125: 1714–1722.
[13]
van Bommel F, Zollner B, Sarrazin C, Spengler U, Hüppe D, et al. (2006) Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatol 44: 318–325.
[14]
Taylor LE, Swan T, Mayer KH (2012) HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis (Suppl 1): S33–S42.
[15]
Pirillo MF, Bassani L, Germinario EA, Mancini MG, Vyankandondera J, et al. (2007) Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. J Med Virol 79: 1797–1801.
[16]
Rwanda Ministry of Health (2011) National HIV Care and Treatment Guidelines, 2011.
[17]
Harania RS, Karuru J, Nelson M, Stebbing J (2008) HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS 19: 1221–1222.
[18]
Nakwagala FN, Kagimu MM (2002) Hepatitis B virus and HIV infections among patients in Mulago hospital. East Afr Med J 79: 68–72.
[19]
Di Bisceglie AM, Maskew M, Schulze D, Reyneke A, McNamara L, et al. (2010) HIV-HBV coinfection among South African patients receiving antiretroviral therapy. Antivir Ther 15: 499–503.
[20]
Firnhaber C, Viana R, Reyneke A, Schultze D, Malope B, et al. (2009) Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis 13: 488–492.
[21]
Laurent C, Bourgeois A, Mpoudi-Ngolé E, Kouanfack C, Ciaffi L, et al. (2010) High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy. HIV Med 11: 85–89.
[22]
Otegbayo JA, Taiwo BO, Akingbola TS, Odaibo GN, Adedapo KS, et al. (2008) Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients. Ann Hepatol 7: 152–156.
[23]
Diop-Ndiaye H, Toure-Kane C, Etard JF, L？ G, Diaw P, et al. (2008) Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol 80: 1332–1336.
[24]
Geretti AM, Patel M, Sarfo FS, Chadwick D, Verheyen J, et al. (2010) Detection of highly prevalent hepatitis B virus coinfection among HIV-positive persons in Ghana. J Clin Microbiol 48: 3223–3230.
[25]
Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, et al. (2007) Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 79: 1464–1471.
[26]
Shire NJ, Rouster SD, Rajici N, Sherman KE (2004) Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 36: 869–875.
[27]
Chadwick D, Stanley A, Sarfo S, Appiah L, Ankcorn M, et al. (2013) Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa. AIDS 27: 139–41.
[28]
Rao H-Y, Sun D-G, Yang R-F, Liu F, Wang J, et al. (2012) Outcome of hepatitis C infection in Chinese paid plasma donors: A 12-19-year cohort study. J Gastroenterol Hepatol 27: 526–532.
[29]
Seremba E, Ocama P, Opio CK, Kagimu M, Thomas DL, et al. (2010) Poor performance of hepatitis C antibody tests in hospital patients in Uganda. J Med Virol 82: 1371–1378.
[30]
Chadwick D, Ankcorn M, Sarfo F, Phillips R, Fox Z, et al. (2012) Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana. J Antimicrob Chemother: doi:10.1093/jac/dks333.
[31]
Hoffman CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, et al. (2009) Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 49: 1268–1273.
[32]
Idoka J, Meloni S, Muazu M, Nimzing L, Badung B, et al. (2009) Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 49: 1268–1273.
[33]
Omland LH, Weis N, Skinh？j P, Laursen A, Christensen PB, et al. (2008) Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study. HIV Med 9: 300–306.
[34]
Ladep NG, Agbaji O, Agaba P, Badung P, Imade G, et al. (2007) Does immunological status affect the prevalence of Hepatitis C virus infection among HIV/AIDS patients? Niger J Med 16: 231–234.
